Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (332)	3/24/1998 6:58:00 AM
From: Don W Stone	Respond to of 507

David: From an investment view point I guess what is significant is the lead in statement to this article. "With more pathogens developing resistance to antibiotics, and with the increasing vulnerability of human populations to infectious diseases, vaccine research has taken on a new urgency."

To: David Bogdanoff who wrote (332)	3/24/1998 8:23:00 AM
From: Don W Stone	Read Replies (1) \| Respond to of 507

David: I spoke to people at the Statenseruminstitut(SSI) in Denmark last week just to get a first hand report on how they were doing with DTaP-IPV. DTaP-IPV was approved in Denmark in late 1996. They started using DTaP-IPV in 1997. They had an "outbreak" of pertussis that year. Of the cases reported during 1997, most had been vaccinated with the old wP vaccine or had not been vaccinated at all and a very few were receiving the new DTaP-IPV vaccine. The individual I spoke to said the NVX vaccine performed extremely well. " The 'outbreak' was stopped". The Danes are extremely happy with the performance of DTaP-IPV. This is the first and only DTaP-IPV vaccine licensed in the world. What will become very evident once Abbott starts telling their story is that NVX's DTaP vaccine has performed extremely well under conditions where there were actually major "outbreaks" of the pertussis disease both in Denmark and in Sweden. I will say that now that I have spoken first hand to those who are using NVX's vaccine I am highly confident that Abbott will dominate the DTaP market in the U.S. . That makes the analyst estimates that are out, that are based on capturing 20% of the DTaP market, very conservative. NVX WILL GET FDA APPROVAL ANYDAY NOW. NVX WILL HAVE ONE FANTASTIC YEAR IN 1999.